Leukemia, Myelomonocytic, Acute — Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
Citation(s)
An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy